SCHEMBL4349925

SCHEMBL4349925

Nc1cc(-c2cccc(C(=O)O)c2)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
GAA P10253 2/20 0.65
KDM4E B2RXH2 1/20 0.65
MEN1 O00255 1/20 0.65
USP2 O75604 1/20 0.65
ALDH1A1 P00352 1/20 0.65
HSP90AA1 P07900 1/20 0.65
MAPT P10636 1/20 0.65
HPGD P15428 1/20 0.65
ALOX15 P16050 1/20 0.65
ALOX12 P18054 1/20 0.65
HTT P42858 1/20 0.65
KMT2A Q03164 1/20 0.65
HSD17B10 Q99714 1/20 0.65
ERN1 O75460 3/20 0.62
KMO O15229 2/20 0.59
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA6 P23280 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406790 0.86 KMO (0.59) LMNAGAAKDM4EALOX15KMT2A
SCHEMBL4336129 0.84 KDM4E (0.66) LMNAGAAKDM4EMEN1USP2
Hydrochloric Acid SCHEMBL10774366 0.82 KDM4E (0.63) LMNAGAAKDM4EMEN1USP2
SCHEMBL29488306 0.81 ALOX15 (0.79) LMNAGAAKDM4EMEN1USP2
SCHEMBL29577419 0.81 KMO (0.87) LMNAGAAERN1KMOCA12
SCHEMBL14683877 0.81 KMO (0.87) LMNAGAAERN1KMOCA12
SCHEMBL16949917 0.81 ALOX15 (0.79) LMNAGAAKDM4EMEN1USP2
SCHEMBL29904709 0.81 KMO (0.86) LMNAGAAHPGDHSD17B10ERN1
SCHEMBL71238 0.81 KMO (0.86) LMNAGAAHPGDHSD17B10ERN1
SCHEMBL30725957 0.81 KMO (0.86) LMNAGAAHPGDHSD17B10ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK LMNA 4580/4885GAA 2853/4885KDM4E 3202/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK LMNA 4580/4885GAA 2853/4885KDM4E 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.